Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 3—March 2022

Neutralizing Enterovirus D68 Antibodies in Children after 2014 Outbreak, Kansas City, Missouri, USA

Robyn A. Livingston1, Christopher J. Harrison1Comments to Author , and Rangaraj Selvarangan1
Author affiliation: Children’s Mercy Hospital Kansas City, Kansas City, Missouri, USA; University of Missouri, Kansas City

Main Article

Table 3

Neutralizing antibody titers for enterovirus D68 clades B1, B2 and D, in patients >24 months of age with and without a clinical diagnosis of asthma, Kansas City, Missouri, USA, 2017

Group No. patients Neutralizing antibody, median (range)*
B1 B2 D
Asthma† 39 9.83 (5.50–10.50) 9.17 (2.50–10.50) 9.17 (3.17–10.50)
No asthma
9.50 (5.83–10.50)
8.83 (2.50–10.50)
8.17 (2.50–10.50)
Total 253 9.50 (5.50–10.50) 9.17 (2.50–10.50) 8.83 (2.50–10.50)

*Antibody titers were measured by using the cell viability kit ATPlite (Perkin Elmer,; the titers shown are the log2 inverse dilution of the lowest antibody concentration with luminescent activity. Includes seronegative patients. †Asthma as noted by clinician diagnosis in electronic medical record. Because no patients had an asthma diagnosis at <24 mo of age, to balance the age distributions of the nonasthma group with the asthma age group, we excluded nonasthma patients <24 mo of age from this analysis.

Main Article

1All authors contributed equally to this article.

Page created: January 03, 2022
Page updated: February 18, 2022
Page reviewed: February 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.